Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Inhibikase Therapeutics (IKT) over the last 4 years, with Q3 2025 value amounting to -$28.7 million.

  • Inhibikase Therapeutics' Cash from Investing Activities fell 123795.88% to -$28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.6 million, marking a year-over-year decrease of 1012415.89%. This contributed to the annual value of -$37.0 million for FY2024, which is 41745.1% down from last year.
  • According to the latest figures from Q3 2025, Inhibikase Therapeutics' Cash from Investing Activities is -$28.7 million, which was down 123795.88% from $9.8 million recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Cash from Investing Activities high stood at $21.1 million for Q1 2025, and its period low was -$38.8 million during Q4 2024.
  • Moreover, its 4-year median value for Cash from Investing Activities was $1.2 million (2022), whereas its average is -$2.8 million.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Cash from Investing Activities soared by 601770.29% in 2023, and later crashed by 173219.02% in 2024.
  • Quarter analysis of 4 years shows Inhibikase Therapeutics' Cash from Investing Activities stood at $5.0 million in 2022, then tumbled by 142.63% to -$2.1 million in 2023, then plummeted by 1732.19% to -$38.8 million in 2024, then grew by 25.84% to -$28.7 million in 2025.
  • Its last three reported values are -$28.7 million in Q3 2025, $9.8 million for Q2 2025, and $21.1 million during Q1 2025.